MétaCan
Menu
Back to cohort
Record W4381597464 · doi:10.3324/haematol.2023.283510

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia

2023· letter· en· W4381597464 on OpenAlexafffund
Tracy Murphy, Jinfeng Zou, Andrea Arruda, Ting Ting Wang, Zhen Zhao, Yangqiao Zheng, Vikas Gupta, Dawn Maze, Caroline McNamara, Mark D. Minden, Aaron D. Schimmer, Hassan Sibai, Karen Yee, José‐Mario Capo‐Chichi, Tracy Stockley, Andre C. Schuh, Scott V. Bratman, Steven M. Chan

Bibliographic record

VenueHaematologica · 2023
Typeletter
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health Network
FundersUniversity of Texas MD Anderson Cancer CenterOntario Institute for Cancer ResearchPrincess Margaret Cancer Foundation
KeywordsIsocitrate dehydrogenaseMyeloid leukemiaMinimal residual diseaseCancer researchIDH1DiseaseRNA splicingGeneResidualMedicineMutationOncologyLeukemiaBiologyInternal medicineGeneticsEnzymeBiochemistryComputer science

Abstract

fetched live from OpenAlex

Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia Accurate risk assessment is crucial for the management of patients with acute myeloid leukemia (AML). 1 The detection of measurable residual disease (MRD) after remission induction therapies has been shown to be an independent risk factor for relapse and death. 2 The use of next-generation sequencing (NGS)-based techniques to detect mutations found in leukemic cells has emerged as a promising approach for MRD assessment.3,4 One of the main challenges of this approach is differentiating between mutations that are found only in the leukemic cell population (henceforth termed "AML-related") and those associated with clonal hematopoiesis (CH).The persistence of CH during remission has not been associated with inferior clinical outcomes.5 Approaches involving genotyping of sorted populations or single cells are required to identify the cellular origins of the mutations, but they are not yet practical for routine clinical use.To overcome this challenge, a common practice is to exclude mutations in three genes, namely DNMT3A, TET2, and ASXL1 (collectively known as DTA), from molecular MRD assessment, 1,3,4 because they are among the most frequently mutated genes in people with clonal hematopoiesis of indeterminate potential (CHIP).6,7 However, mutations in other genes are also found in CHIP carriers.[6][7][8] Moreover, the relative frequencies of CH-related mutations in AML patients differ from those of CHIP carriers who, by definition, do not have any other hematologic abnormalities.5 This discordance is likely because the risk of AML development varies between different CH-related mutations.8 Thus, it is unclear whether DTA mutations are the optimal ones for exclusion in molecular MRD analysis in AML.To address the above uncertainty, we systematically analyzed the impact of exclusion of mutations in 22 myeloid malignancy-associated genes on the difference in clinical outcomes between patients stratified as MRD-positive (MRD POS ) and MRD-negative (MRD NEG ).To perform this analysis, we studied 114 newly diagnosed AML patients who received high-intensity induction chemotherapy and achieved a complete remission.The clinical characteristics of the patients are listed in Online Supplementary Table S1.We performed targeted conventional NGS analysis on DNA extracted from their diagnostic peripheral blood or bone marrow samples.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.008
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.011
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0080.006
Insufficient payload (model declined to judge)0.0030.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.303
Teacher spread0.272 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueHaematologicaSame topicAcute Myeloid Leukemia ResearchFrench-language works237,207